- Senior Investigator, Clinical Genetics Branch
Dr. Greene received a B.A. (English) from Yale College, an M.D. from Tufts University, and completed his training in Internal Medicine at the Massachusetts General Hospital in Boston. He spent three years with the Epidemic Intelligence Service of the U.S. Centers for Disease Control and Prevention, and then came to the National Cancer Institute in 1975 as a Staff Fellow in the Environmental Epidemiology Branch. Dr. Greene completed his medical oncology fellowship at the Medicine Branch, NCI, and is board-certified in both Internal Medicine and Medical Oncology. In 1977, he became a Senior Investigator and, subsequently, Coordinator of Family Studies within the Environmental Epidemiology Branch (EEB). In 1984, Dr. Greene was appointed Deputy Branch Chief of EEB. In 1985, he left government service to enter the private practice of medical oncology and hematology in Sun City, Arizona. In 1991, he joined the faculty of Mayo Clinic Scottsdale as a Professor of Oncology in the Mayo Medical School. While at Mayo, he was a participating investigator with a variety of cooperative oncology groups, including NCCTG, ECOG and NSABP. Dr. Greene became the Principal Investigator for the Mayo Cancer Center’s Familial Cancer Program in 1994. In the fall of 1999, he returned to NCI as the Branch Chief of the newly-created Clinical Genetics Branch. Dr. Greene served as Branch Chief until 2013, and continues to direct studies as a senior investigator within the branch.
- (2020). Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. CANCER RESEARCH. 80(3), 624-638.
- (2008). Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185(her2/neu) and the EGFR-p185(her2/neu) complexes. ONCOGENE. 27(27), 3870-3874.
- (2002). Deoxycholate-based method to screen phage display clones for uninterrupted open reading frames. BIOTECHNIQUES. 33(2), 294-296.
- (2020). Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. GENETICS IN MEDICINE. 22(10), 1653-1666.
- (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. NATURE GENETICS. 52(6), 572-+.
- (2020). Waiting and "weighted down": the challenge of anticipatory loss for individuals and families with Li-Fraumeni Syndrome. Familial Cancer. 19(3), 259-268.
- (2020). Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. GENETIC EPIDEMIOLOGY. 44(5), 442-468.